SCHEMBL6779019

SCHEMBL6779019

C[C@@H]1CC(=O)O[C@@H]1c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.53
CYP2C9 P11712 1/20 0.53
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 4/20 0.45
ALDH1A1 P00352 3/20 0.44
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
AKT1 P31749 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
AR P10275 1/20 0.41
CYP19A1 P11511 1/20 0.41
MAOB P27338 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11309348 1.00 CYP2C19 (0.53) CYP2C19CYP2C9KMT2AMEN1GAA
SCHEMBL21553352 0.78 CYP2C19 (0.80) CYP2C19CYP2C9KMT2AMEN1GAA
SCHEMBL10700032 0.77 LMNA (0.52) CYP2C19CYP2C9KMT2AMEN1ALDH1A1
SCHEMBL7450000 0.76 CYP2C19 (0.53) CYP2C19CYP2C9KMT2AMEN1GAA
SCHEMBL8998580 0.74 CYP2C19 (0.56) CYP2C19CYP2C9KMT2AMEN1GAA
SCHEMBL14619613 0.74 CYP2C19 (0.56) CYP2C19CYP2C9KMT2AMEN1GAA
SCHEMBL15482008 0.74 CYP2C19 (0.56) CYP2C19CYP2C9KMT2AMEN1GAA
Hydrochloric Acid SCHEMBL8972440 0.74 CYP2C19 (0.51) CYP2C19CYP2C9KMT2AMEN1GAA
SCHEMBL14619614 0.74 CYP2C19 (0.56) CYP2C19CYP2C9KMT2AMEN1GAA
Hydrochloric Acid SCHEMBL8622023 0.74 CYP2C19 (0.51) CYP2C19CYP2C9KMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6710190-B1 ANTIEPILEPTIC, ANTIDEPRESSANT, ANXIOLYTIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANALGESIC AGENTS; NEURODEGENERATIVE AND GASTROINTESTINAL DISORDERS; IRRITABLE BOWEL SYNDROME WARNER-LAMBERT COMPANY 2004-03-23 US disclosed